Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five ...

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The Iranian Foreign Minister Abbas Araghchi has condemned US strikes on the country’s nuclear facilities. He said Iran ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The scientist, Dr. Fiona Havers, told colleagues at the Centers for Disease Control and Prevention on Monday that she no ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...